

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

FRESENIUS-KABI USA LLC,
Petitioner,

v.

ASTRAZENECA AB,
Patent Owner.

Case IPR2017-01913
Patent 8,329,680 B2

Before GRACE KARAFFA OBERMANN, ZHENYU YANG, and
ROBERT A. POLLOCK, *Administrative Patent Judges*.

POLLOCK, *Administrative Patent Judge*.

DECISION
Denying Institution of *Inter Partes* Review
37 C.F.R. § 42.108

I. INTRODUCTION

Petitioner Fresenius-Kabi USA LLC (“Petitioner”) filed a Petition requesting an *inter partes* review of claims 1–3 and 6 of U.S. Patent No. 8,329,680 B2 (Ex. 1001, “the ’680 Patent”). Paper 1 (“Pet.”). AstraZeneca AB (“Patent Owner”) filed a Preliminary Response to the Petition. Paper 8 (“Prelim. Resp.”).

Institution of an *inter partes* review is authorized by statute when “the information presented in the petition . . . and any response . . . shows that there is a reasonable likelihood that the petitioner would prevail with respect to at least 1 of the claims challenged in the petition.” 35 U.S.C. § 314; *see* 37 C.F.R. §§ 42.4, 42.108. Upon considering the Petition and the Preliminary Response, we determine that Petitioner has not shown a reasonable likelihood that it would prevail in showing the unpatentability of at least one challenged claim. Accordingly, we decline to institute an *inter partes* review of the ’680 Patent.

A. *Related Applications and Proceedings*

The ’680 Patent shares substantially the same specification with U.S. Patent Nos. 6,774,122 B2 (“the ’122 Patent”), 7,456,160 B2 (“the ’160 Patent”), and 8,466,139 B2 (“the ’139 Patent”), which are related as follows. The ’139 Patent issued from Application No. 13/602,667 (“the ’667 Application”), which is a continuation of Application No. 12/285,887 (“the ’887 Application”) (now the ’680 Patent), which is a continuation of Application No. 10/872,784 (“the ’784 Application”) (now the ’160 Patent), which is a continuation of Application No. 09/756,291 (“the ’291 Application”) (now the ’122 Patent). This chain of continuations was first

filed on January 9, 2001, and each patent in the family claims benefit of foreign priority to applications filed April 12, 2000, and January 10, 2000.

According to the parties, the '680 Patent has been the subject of numerous district court litigations. *See* Pet. 4–5; Paper 6, 2–3. According to Patent Owner, the related '122, '160, and '139 Patents have also been involved in district court proceedings. Paper 6, 3.

Each of the four related patents have also been the subject of *inter partes* review proceedings filed by Mylan Pharmaceuticals, Inc. (“Mylan”). Of these, IPR2016-01316 on the '122 Patent, IPR2016-01324 on the '160 Patent, and IPR2016-01326 on the '139 Patent were terminated before we issued a decision regarding institution. In IPR2016-01325 (“Mylan IPR”) on the '680 Patent, however, we issued a Decision denying institution (“Mylan Decision”), which Petitioner submits in this proceeding as Exhibit 1011 and discusses extensively in the Petition.

The '680 Patent and two related patents also have been the subject of petitions for *inter partes* review filed by InnoPharma Licensing, LLC: IPR2017-00900 on the '680 Patent, IPR2017-00904 on the '122 Patent, and IPR2017-00905 on the '139 Patent. We previously denied each of those petitions.

In addition to the instant Petition challenging claims of the '680 Patent, Petitioner has submitted Petitions challenging claims of the '122 Patent (IPR2017-01910), and the '139 Patent (IPR2017-01912).¹ These petitions are virtually identical to the three petitions filed by InnoPharma Licensing and denied by the Board in IPR2017-00900, IPR2017-00904, and

¹ Petitioner does not presently challenge any claim of the '160 Patent.

IPR2017-00905, respectively. Paper 7, 3–4; *see id.* at 4 (“Petitioner copied verbatim the earlier-filed petitions, and supporting declarations, submitted by InnoPharma Licensing.”). Petitioner filed requests for joinder with the respective *inter partes* reviews filed by InnoPharma (Paper 3), which we denied (Paper 7).

B. The '680 Patent and Relevant Background

The Specification of the '680 Patent discloses “an extended release pharmaceutical formulation adapted for intramuscular injection comprising fulvestrant”² for the treatment of “benign or malignant diseases of the breast or reproductive tract, preferably treating breast cancer.” Ex. 1001, 10:65–11:32. Fulvestrant is also known in the art as ICI 182,780 or 7 α -[9-(4,4,5,5,5-pentafluoropentylsulphanyl)nonyl]oestra-1,3,5(10)-triene-3,17- β -diol, and is the active ingredient in AstraZeneca’s FASLODEX product for “[t]reatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.” *Id.* at Abstract, 1:65–2:6; Ex. 1021,³ 1, 13.

As of the filing date of the '680 Patent, nonsteroidal antiestrogens, most particularly, tamoxifen, were used in the treatment of hormonal-dependent breast cancers. *See* Ex. 1001, 1:23–36; Prelim. Resp. 21. In some hormonal-dependent cancers, estrogen bound to estrogen receptors (ERs) stimulates tumor growth. *See* Pet. 12; Prelim. Resp. 20. Tamoxifen is a selective estrogen receptor modulator or SERM, meaning that it acts as an

² The Specification defines “extended release” to mean that “at least two weeks, at least three weeks, and, preferably at least four weeks of continuous release of fulvestrant is achieved.” *Id.* at 9:29–31.

³ FASLODEX Prescribing Information, Rev. 11/2012.

estrogen antagonist in these cancers, blocking the binding of estrogen to its receptors. Prelim Resp. 21–22. As of the filing date of the '680 Patent, however, researchers were seeking alternative treatments, including fulvestrant, for estrogen-dependent breast cancers because resistance to tamoxifen tends to develop over time, and because tamoxifen treatment could adversely affect bone and uterine tissue. See Ex. 1001, 2:13–31; Pet. 22; Prelim. Resp. 21; Ex. 1015 ¶¶ 68–74. Unlike tamoxifen, fulvestrant is a “pure” antiestrogen or ERD (estrogen receptor downregulator), which does not display the partial ER agonist activity of tamoxifen. See Ex. 1001, 2:13–19; Ex. 1015 ¶¶ 68, 85.

The Specification discloses that intramuscular administration of fulvestrant in aqueous suspension results in a clinically insufficient release rate and “extensive local tissue irritation” because fulvestrant particles are present at the injection site. Ex. 1001, 8:62–9:5. And while the “solvating ability of castor oil for steroidal compounds is known” (*id.* at 5:48–53), a monthly depot injection made by dissolving fulvestrant in castor oil alone would require formulation volumes of at least 10 ml “to achieve a high enough concentration to dose a patient in a low volume injection and achieve a therapeutically significant release rate.” *Id.* at 5:54–6:2. In addressing these problems, the '680 Patent states:

With the addition of high concentrations of an alcohol concentrations of $>50 \text{ mgml}^{-1}$ of fulvestrant in a castor oil formulation is achievable, thereby giving an injection volumes of $<5 \text{ ml}$ We have surprisingly found that the introduction of a non-aqueous ester solvent which is miscible in the castor oil and an alcohol surprisingly eases the solubilisation of fulvestrant into a concentration of at least 50 mgml^{-1} The finding is surprising since the solubility of fulvestrant in non-aqueous ester

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.